Shares of Kraken Robotics (2KQ.F) slid 3.0% to €3.69 on July 9, pulling back sharply after a multi-day rally that erupted when the Canadian marine-technology firm closed its transformative acquisition and raised its outlook. The stock is now down roughly 7.4% from its recent peak, a textbook case of investors cashing in gains while sizing up whether the new, much larger Kraken can deliver.

A CA$615 Million Deal Doubles the Company Overnight

Kraken completed its purchase of UK-based Covelya Group for approximately CA$615 million — about CA$480 million in cash and CA$135 million via 15.9 million shares priced at CA$8.50 apiece.

Covelya, which operates through subsidiaries including Sonardyne and EIVA, designs and supports high-performance underwater technology for both defense and commercial clients.

The cash was funded by a CA$402.5 million public offering and a new CA$125 million credit facility. That's a lot of debt and dilution for a company that generated just CA$102 million in revenue last year.

Guidance Nearly Doubles — But Margins Shrink

Kraken raised its 2026 revenue outlook to CA$290–$320 million from CA$165–$175 million, and lifted adjusted EBITDA guidance to CA$65–$75 million from CA$40–$50 million. That sounds impressive until you check the margins: adjusted EBITDA margin guidance was cut to 22–23%, down from 24–29% before. In other words, Covelya is a lower-margin business that boosts the top line faster than it grows profits.

A Combined Order Book Covers Most of the Target — But Not All

Combined 2026 orders total roughly CA$292 million — about 96% of the updated revenue midpoint. That's reassuring, yet the company hasn't guaranteed all orders will convert to 2026 revenue.

Revenue is expected to be weighted toward the second half of the year , meaning execution risk is back-loaded.

The Payoff Hinges on Integration and Defense Spending

Management projects low-to-mid double-digit earnings-per-share improvement in 2027, including about CA$10 million in cost synergies over 24 months.

Meanwhile, the stock trades roughly 21.5% below the CA$8.50 share price used to pay Covelya's sellers , signaling the market isn't yet fully buying the synergy story. Until Kraken proves it can integrate six new subsidiaries, hit second-half targets, and convert orders into cash, the pullback looks less like panic and more like healthy skepticism.